AIMS: Cyclic GMP (cGMP)-specific phosphodiesterase 5 (PDE5) inhibition by sildenafil (SIL) activates myocardial cGMP-dependent protein kinase G (PKG) and blunts cardiac hypertrophy. To date, the only documented target of PKG in myocardium is the serine-threonine phosphatase calcineurin (Cn), which is central to pathological cardiac hypertrophy. We tested whether Cn suppression is necessary in order to observe anti-hypertrophic effects of SIL. METHODS AND RESULTS: Mice lacking the Cn-Abeta subunit (CnAbeta(-/-)) and wild-type (WT) controls were subjected to transverse aorta constriction (TAC) with or without SIL (200 mg/kg/day, p.o.) for 3 weeks. TAC-induced elevation of Cn expression and activity in WT was absent in CnAbeta(-/-) hearts, and the latter accordingly developed less cardiac hypertrophy (50 vs. 100% increase in heart weight/tibia length, P < 0.03) and chamber dilation. SIL remained effective in CnAbeta(-/-) mice, increasing PKG activity similarly as in WT, suppressing hypertrophy and fetal gene expression, and enhancing heart function without altering afterload. TAC-stimulated calcium-calmodulin kinase II, Akt, and glycogen synthase kinase 3beta in both groups (the first rising more in CnAbeta(-/-) hearts), and SIL also suppressed these similarly. Activation of extracellular signal-regulated kinase observed in WT-TAC but not CnAbeta(-/-) hearts was also suppressed by SIL. CONCLUSION: PDE5A inhibition and its accompanying PKG activation blunt hypertrophy and improve heart function even without Cn activation. This occurs by its modulation of several alternative pathways which may result from concomitant distal targeting, or activity against a common proximal node.
AIMS: Cyclic GMP (cGMP)-specific phosphodiesterase 5 (PDE5) inhibition by sildenafil (SIL) activates myocardial cGMP-dependent protein kinase G (PKG) and blunts cardiac hypertrophy. To date, the only documented target of PKG in myocardium is the serine-threonine phosphatase calcineurin (Cn), which is central to pathological cardiac hypertrophy. We tested whether Cn suppression is necessary in order to observe anti-hypertrophic effects of SIL. METHODS AND RESULTS:Mice lacking the Cn-Abeta subunit (CnAbeta(-/-)) and wild-type (WT) controls were subjected to transverse aorta constriction (TAC) with or without SIL (200 mg/kg/day, p.o.) for 3 weeks. TAC-induced elevation of Cn expression and activity in WT was absent in CnAbeta(-/-) hearts, and the latter accordingly developed less cardiac hypertrophy (50 vs. 100% increase in heart weight/tibia length, P < 0.03) and chamber dilation. SIL remained effective in CnAbeta(-/-) mice, increasing PKG activity similarly as in WT, suppressing hypertrophy and fetal gene expression, and enhancing heart function without altering afterload. TAC-stimulated calcium-calmodulin kinase II, Akt, and glycogen synthase kinase 3beta in both groups (the first rising more in CnAbeta(-/-) hearts), and SIL also suppressed these similarly. Activation of extracellular signal-regulated kinase observed in WT-TAC but not CnAbeta(-/-) hearts was also suppressed by SIL. CONCLUSION:PDE5A inhibition and its accompanying PKG activation blunt hypertrophy and improve heart function even without Cn activation. This occurs by its modulation of several alternative pathways which may result from concomitant distal targeting, or activity against a common proximal node.
Authors: Y Zou; A Yao; W Zhu; S Kudoh; Y Hiroi; M Shimoyama; H Uozumi; O Kohmoto; T Takahashi; F Shibasaki; R Nagai; Y Yazaki; I Komuro Journal: Circulation Date: 2001-07-03 Impact factor: 29.690
Authors: Orlando F Bueno; Benjamin J Wilkins; Kevin M Tymitz; Betty J Glascock; Thomas F Kimball; John N Lorenz; Jeffery D Molkentin Journal: Proc Natl Acad Sci U S A Date: 2002-03-19 Impact factor: 11.205
Authors: B A Rothermel; T A McKinsey; R B Vega; R L Nicol; P Mammen; J Yang; C L Antos; J M Shelton; R Bassel-Duby; E N Olson; R S Williams Journal: Proc Natl Acad Sci U S A Date: 2001-03-13 Impact factor: 11.205
Authors: Tong Zhang; Eric N Johnson; Yusu Gu; Michael R Morissette; Valerie P Sah; Marisa S Gigena; Darrell D Belke; Wolfgang H Dillmann; Terry B Rogers; Howard Schulman; John Ross; Joan Heller Brown Journal: J Biol Chem Date: 2001-11-02 Impact factor: 5.157
Authors: Christopher L Antos; Timothy A McKinsey; Norbert Frey; William Kutschke; John McAnally; John M Shelton; James A Richardson; Joseph A Hill; Eric N Olson Journal: Proc Natl Acad Sci U S A Date: 2002-01-08 Impact factor: 11.205
Authors: Orlando F Bueno; Eva van Rooij; Jeffery D Molkentin; Pieter A Doevendans; Leon J De Windt Journal: Cardiovasc Res Date: 2002-03 Impact factor: 10.787
Authors: Takashi Matsui; Ling Li; Justina C Wu; Stuart A Cook; Tomohisa Nagoshi; Michael H Picard; Ronglih Liao; Anthony Rosenzweig Journal: J Biol Chem Date: 2002-04-09 Impact factor: 5.157
Authors: Beate Fiedler; Suzanne M Lohmann; Albert Smolenski; Stephan Linnemuller; Burkert Pieske; Frank Schroder; Jeffery D Molkentin; Helmut Drexler; Kai C Wollert Journal: Proc Natl Acad Sci U S A Date: 2002-08-12 Impact factor: 11.205
Authors: Rachel P Heilman; Megan B Lagoski; Keng Jin Lee; Joann M Taylor; Gina A Kim; Sara K Berkelhamer; Robin H Steinhorn; Kathryn N Farrow Journal: Am J Physiol Heart Circ Physiol Date: 2015-04-10 Impact factor: 4.733
Authors: Luca Di Lullo; Antonio Gorini; Domenico Russo; Alberto Santoboni; Claudio Ronco Journal: Cardiorenal Med Date: 2015-07-15 Impact factor: 2.041